Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously confirmed histological diagnosis of locally advanced or metastatic papillary or follicular thyroid carcinoma, without anaplastic component. Tumor sample available for centralized exploratory analysis.~* Presence of one or more measurable lesions at least 1 cm in the longest diameter by spiral CT scan or 2 cm with conventional techniques.~* Progressive disease following RAI131 or patient unsuitable for RAI131 after surgery.~* Serum TSH \<0.5 mU/L.~Exclusion Criteria:~* Major surgery within 4 weeks before randomization.~* Prior chemotherapy within the last 4 weeks prior to randomization.~* RAI131 therapy within 3 months in patients with radioiodine uptake.~* Radiation therapy within the last 4 weeks prior to randomization (with the exception of palliative radiotherapy).~* Serum bilirubin \>1.5\*the upper limit of reference range (ULRR).~* Creatinine clearance \< 30 ml/min (calculated by Cockcroft-Gault formula).~* Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) greater than 2.5\*ULRR, or greater than 5.0\*ULRR if judged by the investigator to be related to liver metastases.~* Clinically significant cardiovascular event (eg myocardial infarction), superior vena cava \[SVC\] syndrome, New York Heart Association \[NYHA\] classification of heart failure \>II within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.~* History of arrhythmia (multifocal premature ventricular contractions \[PVCs\], bigeminy, trigeminy, ventricular tachycardia or uncontrolled atrial fibrillation), which is symptomatic or requires treatment (CTCAE grade 3), , or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication are permitted.~* Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vandetanib (ZD6474) (Type: EXPERIMENTAL): vandetanib (ZD6474) 300 mg per os once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).